Skip to content
Study details
Enrolling now

Standard Versus High Dose ED-Initiated Buprenorphine Induction

Yale University
NCT IDNCT06494904ClinicalTrials.gov data as of Apr 2026
Phase

Phase 3

Target enrollment

360

Study length

about 4.1 years

Ages

18–65

Locations

5 sites in CA, ME, NJ +1

About this study

Researchers are testing whether a higher dose of buprenorphine, started in the emergency department (ED), helps more people start opioid treatment sooner than a standard dose. The trial will also measure how much withdrawal symptoms and cravings are reduced with both doses.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Buprenorphine
PhasePhase 3
DrugBuprenorphine
Routeinjection

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low9%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

buprenorphine

Drug routes

injection

Body systems

Psychiatry / Mental Health